Esperion Therapeutics, a privately held biotechnology company in Plymouth, Monday announced positive results from a Phase 2 clinical trial for its potential cholesterol buster, ETC-1002.
Metabolic Solutions Development Co. LLC announced it has received a $1.1 million multi-year Small Business Technology Transfer Program grant from the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health. The company will use the money to develop its drug candidate for fatty liver disease.
Kalamazoo-based NephRx Corp. announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that […]
Officials at the Barbara Ann Karmanos Cancer Center in Detroit said Wednesday that they had been selected to be one of 50 sites in the United States to offer the new U.S. Food and Drug […]